Around the world, 100 companies have debuted weight-loss medications, which have become a multimillion-dollar business. Novo Nordisk’s Ozempic is currently the best-known, but it’s far from the only option
The semaglutide craze is a global phenomenon, but among its unwanted side effects is a premature aging of the face. Health professionals have found themselves administering anti-aging treatments to an ever-younger clientele
Citi estimates that the fight against obesity will generate revenue of $158 billion in 2035. The main risk for the sector is the difficulty in guaranteeing supply
During trials, patients showed reduced appetite and even an aversion towards food generally. This has the potential to affect giant companies such as Nestlé and Cadbury
Patients given monthly infusions of Eli Lilly and Co.’s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study